Study to identify genomic markers associated with clinical response to ADCT-402 (loncastuximab tesirine) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) LAUSANNE, Switzerland, Aug. 6, 2019 /PRNewswire/ — ADC Therapeutics, an oncology drug...
When an existing ClinOne client enabled our MD Referral application to support a global phase II study across the United States, Europe and Australia their results far surpassed everyone’s expectations. The sponsor’s aggressive goal to randomize 400 patients diagnosed...
U.S. FDA submission for children planned for 4Q 2019 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a pivotal Phase 3 trial evaluating Dupixent® (dupilumab) to treat severe atopic dermatitis in children aged 6 to 11 years met its...
Eureka Therapeutics, Inc., a clinical stage biopharmaceutical company developing novel T-cell therapies that harness the evolutionary power of the immune system, today announced initiation of Phase 1/2 clinical trial of ET140202 ARTEMIS™ T-Cell therapy in liver cancer...
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced dosing of the first patient in the SKYLIGHT 1™ Phase 3 pivotal trial for fezolinetant, an investigational oral, non-hormonal compound being studied for...
Email
Text